Attention deficit/hyperactivity disorder (ADHD), with the main symptoms being inattention, impulsiveness or hyperactivity, has long been considered a disorder limited to childhood. It is now known that ADHD can persist into adulthood in 50-80% of people with ADHD, with varying degrees of severity and symptoms, and is associated with other mental and somatic illnesses. With a prevalence of 2.5%, it is even a frequently occurring disease. ADHD is mainly caused by genetic risks and early environmental influences with an impact on brain development. At the individual patient level, however, there are different profiles in terms of etiopathogenetic, clinical, neuropsychological and brain imaging findings.
The aim of the FG is to develop innovative therapeutic approaches based on new findings on the development of symptoms in a translational - ideally personalised - approach and to make them available to patients as quickly as possible.
The main methods used in the translational FG are: genetic biomarker research, multimodal cerebral imaging (especially functional MRI), neural stimulation methods (e.g. alternating current stimulation), clinical-pharmacological and non-pharmacological studies (psychotherapy), digitalised medicine, symptom-based basic research in virtual reality.
https://www.adhd-federation.org/about-us/board.html (Prof. Philipsen founding member)
https://adhs-deutschland.de/Home.aspx (Prof. Philipsen scientific advisory board)